Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00483470 | Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose | PHASE3 | COMPLETED | 720 | — | — | Jun 1, 2007 | Aug 1, 2008 | Jan 22, 2014 | 3 | China |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Hepatitis A vaccine AVAXIM 80U | BIOLOGICAL | 0.5 mL, Intramuscular |
| Hepatitis A vaccine (HAVRIX 720) | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : Inclusion criteria to be checked at the screening visit (SC): 1. Toddlers, children and adolescents: Sub-Group 1: from 12 months to 3 years of age on the day of inclusion Sub-Group 2: from 4 to 6 years of age on the day of inclusion Sub-Group 3: from 7 to 9 years o...